RecruitingPancreas CancerLung CancerRenal Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Sponsor: Dana-Farber Cancer Institute
You may qualify if…
- ✓ Participants must have a confirmed malignancy requiring stereotactic body radiation therapy. See specific disease site cohorts for more details.
- ✓ Tumor size ≤ 7cm
- ✓ Age 18 years of older.
- ✓ ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
- ✓ Ability to understand and the willingness to sign a written informed consent document.
- ✓ Specific eligibility requirements for each disease site with be covered in each specific cohort.
You may not qualify if…
- ✕ Specific exclusion requirements for each disease site with be covered in each specific cohort
- ✕ History of allergic reactions attributed to gadolinium-based IV contrast.
- ✕ \-- Note: If a patient will not receive contrast, this is not applicable
- ✕ Pregnant women are excluded from this study.
- ✕ Severe claustrophobia or anxiety
- ✕ Participants who cannot undergo an MRI
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT04115254 · last updated 2025-11-13